Akebia Therapeutics, Inc. (AKBA) Financial Statements (2024 and earlier)

Company Profile

Business Address 245 FIRST STREET
CAMBRIDGE, MA 02142
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments53,57256,95390,466144,761143,893174,562
Cash and cash equivalents53,57256,95390,466144,761143,893174,562
Receivables19,57217,78140,28423,09481,86964,582
Inventory, net of allowances, customer advances and progress billings20,90520,60421,56840,03936,27239,422
Inventory20,90520,60421,56840,03936,27239,422
Prepaid expense 15,600     
Other undisclosed current assets8,79825,38132,86429,61842,12924,121
Total current assets:118,447120,719185,182237,512304,163302,687
Noncurrent Assets
Operating lease, right-of-use asset14,39127,95829,15830,33731,49432,631
Property, plant and equipment4,4194,8165,2145,6226,0356,451
Intangible assets, net (including goodwill)113,107118,127131,128136,148145,159154,169
Goodwill59,04455,05359,04455,05355,05355,053
Intangible assets, net (excluding goodwill)54,06363,07472,08481,09590,10699,116
Other noncurrent assets3,3485,2385,37226,27534,95339,418
Total noncurrent assets:135,265156,139170,872198,382217,641232,669
TOTAL ASSETS:253,712276,858356,054435,894521,804535,356
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities68,18458,94493,798116,212123,111129,126
Employee-related liabilities9,1406,883
Accounts payable11,77612,57718,02119,70824,94419,466
Accrued liabilities56,40846,36775,77787,36491,284109,660
Deferred revenue   3,7381,2655,04710,440
Debt24,00024,00032,00065,94798,15897,848
Other undisclosed current liabilities    4,5417,36416,500
Total current liabilities:92,18482,944129,536187,965233,680253,914
Noncurrent Liabilities
Long-term debt and lease obligation18,48626,29634,07830,68331,73332,581
Long-term debt, excluding current maturities18,48626,29634,078   
Liabilities, other than long-term debt71,91883,357128,966117,609110,185143,099
Deferred revenue43,29643,29643,29643,29643,29665,356
Customer refund liability   40,992   
Other liabilities17,14212,64315,71774,31366,88977,743
Operating lease, liability11,48027,41828,96130,68331,73332,581
Other undisclosed noncurrent liabilities97,93198,61358,24485,78483,90679,646
Total noncurrent liabilities:188,335208,266221,288234,076225,824255,326
Total liabilities:280,519291,210350,824422,041459,504509,240
Equity
Equity, attributable to parent(26,807)(14,352)5,23013,85362,30026,116
Common stock222222
Additional paid in capital1,568,2601,564,7701,562,2471,559,2061,555,7881,548,880
Accumulated other comprehensive income666666
Accumulated deficit(1,595,075)(1,579,130)(1,557,025)(1,545,361)(1,493,496)(1,522,772)
Total equity:(26,807)(14,352)5,23013,85362,30026,116
TOTAL LIABILITIES AND EQUITY:253,712276,858356,054435,894521,804535,356

Income Statement (P&L) ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
Revenues56,37640,12755,06248,964126,75961,699
Cost of revenue
(Cost of Goods and Services Sold)
(17,284)(19,484)2,323(37,947)(18,600)(31,344)
Gross profit:39,09220,64357,38511,017108,15930,355
Operating expenses(48,088)(45,581)(65,399)(59,191)(74,257)(88,848)
Operating income (loss):(8,996)(24,938)(8,014)(48,174)33,902(58,493)
Nonoperating income (expense)
(Other Nonoperating Income (Expense))
(10)2824341,1674111,134
Interest and debt expense    (906)  
Income (loss) from continuing operations before equity method investments, income taxes:(9,006)(24,656)(7,580)(47,913)34,313(57,359)
Other undisclosed loss from continuing operations before income taxes   (15,687)   
Income (loss) from continuing operations:(9,006)(24,656)(23,267)(47,913)34,313(57,359)
Income (loss) before gain (loss) on sale of properties:(47,913)34,313(57,359)
Net income (loss):(9,006)(24,656)(23,267)(47,913)34,313(57,359)
Other undisclosed net income (loss) attributable to parent(2,166)(1,561)14,051(3,952)(5,037)(5,062)
Net income (loss) available to common stockholders, diluted:(11,172)(26,217)(9,216)(51,865)29,276(62,421)

Comprehensive Income ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
Net income (loss):(9,006)(24,656)(23,267)(47,913)34,313(57,359)
Comprehensive income (loss):(9,006)(24,656)(23,267)(47,913)34,313(57,359)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(2,166)(1,561)14,051(3,952)(5,037)(5,062)
Comprehensive income (loss), net of tax, attributable to parent:(11,172)(26,217)(9,216)(51,865)29,276(62,421)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: